Contact Us

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Affiliations
  • 1Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • 2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • 3Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA.
  • 4University of Warwick Trials Unit, Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • 5Department of Hematology, Saint-Louis Institute for Research, Université Paris Cité, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • 6Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • 7Service d’Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris and Université de Paris Cité, Paris, France.
  • 8Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
  • 9Department of Pathology, Massachusetts General Hospital, Boston, MA.
  • 10Department of Medicine and Comprehensive Cancer Center, The University of Chicago, Chicago, IL.
  • 11Department of Medicine, Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY.
  • 12Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
  • 13Division of Hematology and Medical Oncology, University of Leipzig, Leipzig, Germany.
  • 14Department of Hematology, Amsterdam University Medical Center, Location Vrije Universiteit Medical Center, Amsterdam, The Netherlands.
  • 15Department of Internal Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany.
  • 16Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
  • 17Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • 18Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • 19Department of Hematology, Medical University of Lodz, Lodz, Poland.
  • 20Department of Haematology, Peter MacCallum Cancer Centre, The Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia.
  • 21Department of Hematology, Erasmus University Medical Center Rotterdam and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Published on:

August 12, 2024

Abstract

The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.